Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
11.30
+0.18 (1.59%)
Mar 13, 2025, 4:00 PM EDT - Market closed
Maze Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | 55.23 | -100.42 | -114.94 |
| Depreciation & Amortization | 3.57 | 4.09 | 3.82 |
| Loss (Gain) From Sale of Investments | - | - | 2.4 |
| Loss (Gain) on Equity Investments | - | - | 3.54 |
| Stock-Based Compensation | 9.35 | 8.75 | 6.74 |
| Other Operating Activities | 14.41 | 7.07 | 2.48 |
| Change in Accounts Payable | -1.05 | 0.4 | -3.78 |
| Change in Other Net Operating Assets | -3.75 | -6.72 | 0.54 |
| Operating Cash Flow | 77.76 | -86.83 | -99.2 |
| Capital Expenditures | -0.58 | -0.44 | -1.97 |
| Investment in Securities | - | - | -1.2 |
| Investing Cash Flow | -0.58 | -0.44 | -3.17 |
| Long-Term Debt Issued | - | 16.18 | - |
| Net Debt Issued (Repaid) | 40.65 | 16.18 | - |
| Issuance of Common Stock | 0.68 | 0.21 | 0.15 |
| Financing Cash Flow | 38.77 | 16.39 | 1.73 |
| Net Cash Flow | 115.96 | -70.88 | -100.65 |
| Free Cash Flow | 77.19 | -87.27 | -101.17 |
| Free Cash Flow Per Share | 3.38 | -3.95 | -5.22 |
| Levered Free Cash Flow | - | -52.55 | - |
| Unlevered Free Cash Flow | - | -52.55 | - |
| Change in Net Working Capital | - | 3.35 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.